{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T11:55:00Z","timestamp":1785412500791,"version":"3.56.0"},"reference-count":59,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Telethon Cyprus"},{"DOI":"10.13039\/501100004117","name":"A.G. Leventis Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004117","id-type":"DOI","asserted-by":"crossref"}]},{"id":[{"id":"https:\/\/ror.org\/01qkhz224","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Background: Congenital Adrenal Hyperplasia (CAH) is a group of autosomal recessive disorders caused by impaired adrenal steroidogenesis, most frequently due to pathogenic variants in the CYP21A2 gene leading to 21-hydroxylase deficiency (21-OHD). Epidemiology and management vary across the Mediterranean Basin as a result of genetic and healthcare differences. Objective: To provide an overview of the epidemiology, diagnostic approaches and treatment patterns of CAH in Mediterranean countries. Methods: A structured review of the literature was performed using PubMed, using combined disease-related, geographic and methodological terms. Eligible studies reporting on epidemiology, diagnosis, or management of CAH were included. Data on study design, population characteristics, incidence, diagnostics, genetics and treatment availability were extracted. Results: Data were collected from 23 Mediterranean and neighboring regions covering over 8.7 million screened newborns. In countries with established newborn screening (e.g., Spain, Italy, France, Greece), the incidence of classic CAH ranged from 1:10,000 to 1:25,000 live births. Higher rates were reported in parts of North Africa and the Eastern Mediterranean. Diagnostic set-up and access to biochemical and genetic confirmation varied widely. Hydrocortisone remains the primary therapy, while access to mineralocorticoids and modified-release glucocorticoids differed across settings. Conclusions: Overall, considerable heterogeneity in CAH epidemiology and care exists across the Mediterranean region. Genetic factors such as founder effects, consanguinity and healthcare organization contribute to these differences. Expanding newborn screening, improving diagnostics and availability to treatments are critical to reducing disparities in CAH care.<\/jats:p>","DOI":"10.3390\/ph19050741","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T21:07:16Z","timestamp":1778274436000},"page":"741","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Congenital Adrenal Hyperplasia in the Mediterranean: A Concise Overview"],"prefix":"10.3390","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4590-4778","authenticated-orcid":false,"given":"Pavlos","family":"Fanis","sequence":"first","affiliation":[{"name":"Department of Molecular Genetics, Function and Therapy, The Cyprus Institute of Neurology and Genetics, Nicosia 1683, Cyprus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicos","family":"Skordis","sequence":"additional","affiliation":[{"name":"Department of Molecular Genetics, Function and Therapy, The Cyprus Institute of Neurology and Genetics, Nicosia 1683, Cyprus"},{"name":"School of Medicine, University of Nicosia, Nicosia 2417, Cyprus"},{"name":"Division of Paediatric Endocrinology, Paedi Center for Specialized Paediatrics, Nicosia 2024, Cyprus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0836-5579","authenticated-orcid":false,"given":"Marios","family":"Tomazou","sequence":"additional","affiliation":[{"name":"Department of Bioinformatics, The Cyprus Institute of Neurology and Genetics, Nicosia 1683, Cyprus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonidas A.","family":"Phylactou","sequence":"additional","affiliation":[{"name":"Department of Molecular Genetics, Function and Therapy, The Cyprus Institute of Neurology and Genetics, Nicosia 1683, Cyprus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6890-8395","authenticated-orcid":false,"given":"Vassos","family":"Neocleous","sequence":"additional","affiliation":[{"name":"Department of Molecular Genetics, Function and Therapy, The Cyprus Institute of Neurology and Genetics, Nicosia 1683, Cyprus"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1056\/NEJMra1909786","article-title":"Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency","volume":"383","author":"Merke","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1210\/endrev\/bnab016","article-title":"Congenital Adrenal Hyperplasia-Current Insights in Pathophysiology, Diagnostics, and Management","volume":"43","author":"Speiser","year":"2022","journal-title":"Endocr. Rev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S2213-8587(13)70007-X","article-title":"One hundred years of congenital adrenal hyperplasia in Sweden: A retrospective, population-based cohort study","volume":"1","author":"Gidlof","year":"2013","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/cen.15009","article-title":"Rare forms of congenital adrenal hyperplasia","volume":"101","author":"Guran","year":"2024","journal-title":"Clin. Endocrinol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0140-6736(22)01330-7","article-title":"Congenital adrenal hyperplasia","volume":"401","author":"Auer","year":"2023","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1159\/000526401","article-title":"Ethnic and National Differences in Congenital Adrenal Hyperplasia Incidence: A Systematic Review and Meta-Analysis","volume":"96","author":"Sheets","year":"2023","journal-title":"Horm. Res. Paediatr."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1210\/jc.2018-01865","article-title":"Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society Clinical Practice Guideline","volume":"103","author":"Speiser","year":"2018","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"100598","DOI":"10.1016\/j.lanepe.2023.100598","article-title":"Epidemiology and diagnostic trends of congenital adrenal hyperplasia in Denmark: A retrospective, population-based study","volume":"28","author":"Berglund","year":"2023","journal-title":"Lancet Reg. Health Eur."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1542\/peds.81.6.866","article-title":"Worldwide experience in newborn screening for classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency","volume":"81","author":"Pang","year":"1988","journal-title":"Pediatrics"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/cge.12153","article-title":"High carrier frequency of 21-hydroxylase deficiency in Cyprus","volume":"84","author":"Phedonos","year":"2013","journal-title":"Clin. Genet."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1038\/gim.2017.46","article-title":"Revisiting the prevalence of nonclassic congenital adrenal hyperplasia in US Ashkenazi Jews and Caucasians","volume":"19","author":"Morissette","year":"2017","journal-title":"Genet. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/ejendo\/lvag004","article-title":"Contemporary global management of 21-hydroxylase deficiency congenital adrenal hyperplasia in early infancy: A multi-national registry study","volume":"194","author":"Lim","year":"2026","journal-title":"Eur. J. Endocrinol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.ymgme.2006.12.005","article-title":"Ethnic-specific distribution of mutations in 716 patients with congenital adrenal hyperplasia owing to 21-hydroxylase deficiency","volume":"90","author":"Wilson","year":"2007","journal-title":"Mol. Genet. Metab."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Livadas, S., and Bothou, C. (2019). Management of the Female With Non-classical Congenital Adrenal Hyperplasia (NCCAH): A Patient-Oriented Approach. Front. Endocrinol., 10.","DOI":"10.3389\/fendo.2019.00366"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s40618-014-0223-1","article-title":"Genetic defects of the CYP21A2 gene in girls with premature adrenarche","volume":"38","author":"Skordis","year":"2015","journal-title":"J. Endocrinol. Investig."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.4103\/2230-8210.145077","article-title":"Phenotypic variability of hyperandrogenemia in females heterozygous for CYP21A2 mutations","volume":"18","author":"Neocleous","year":"2014","journal-title":"Indian J. Endocrinol. Metab."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12020-025-04341-5","article-title":"Non-classical congenital adrenal hyperplasia: Current insights into clinical implications, diagnosis and treatment","volume":"90","author":"Loli","year":"2025","journal-title":"Endocrine"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"msac108","DOI":"10.1093\/molbev\/msac108","article-title":"Population Genetics and Signatures of Selection in Early Neolithic European Farmers","volume":"39","author":"Childebayeva","year":"2022","journal-title":"Mol. Biol. Evol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/nature16152","article-title":"Genome-wide patterns of selection in 230 ancient Eurasians","volume":"528","author":"Mathieson","year":"2015","journal-title":"Nature"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"K17","DOI":"10.1530\/EJE-21-0554","article-title":"Prenatal dexamethasone treatment for classic 21-hydroxylase deficiency in Europe","volume":"186","author":"Nowotny","year":"2022","journal-title":"Eur. J. Endocrinol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Botelho Barra, C., Villela, T.R., Soares, N.F., Colosimo, E.A., Belisario, A.R., e Silva, A.C.S., and Silva, I.N. (2022). Pharmacogenomic markers of glucocorticoid response in congenital adrenal hyperplasia. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0279298"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e007195","DOI":"10.1136\/bmjgh-2021-007195","article-title":"Access to fludrocortisone and to hydrocortisone in children with congenital adrenal hyperplasia in the WHO Eastern Mediterranean Region: It takes a village","volume":"6","author":"Rowlands","year":"2021","journal-title":"BMJ Glob. Health"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1089\/gtmb.2011.0381","article-title":"Overview of genetic defects in endocrinopathies in the island of Cyprus; evidence of a founder effect","volume":"16","author":"Shammas","year":"2012","journal-title":"Genet. Test. Mol. Biomark."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1530\/eje.0.1490137","article-title":"Mutational spectrum of congenital adrenal hyperplasia in Slovenian patients: A novel Ala15Thr mutation and Pro30Leu within a larger gene conversion associated with a severe form of the disease","volume":"149","author":"Dolzan","year":"2003","journal-title":"Eur. J. Endocrinol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1056\/NEJM198807073190104","article-title":"Molecular genetic analysis of nonclassic steroid 21-hydroxylase deficiency associated with HLA-B14,DR1","volume":"319","author":"Speiser","year":"1988","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.gene.2012.07.027","article-title":"Steroid 21-hydroxylase gene mutational spectrum in 50 Tunisian patients: Characterization of three novel polymorphisms","volume":"507","author":"Riepe","year":"2012","journal-title":"Gene"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1093\/tropej\/fmq064","article-title":"Congenital adrenal hyperplasia in Alexandria, Egypt: A high prevalence justifying the need for a community-based newborn screening program","volume":"57","author":"Tayel","year":"2011","journal-title":"J. Trop. Pediatr."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s40618-020-01271-z","article-title":"Genetic profiling of CAH Egyptian children: Rapid guide to clinical interpretation of common mutations","volume":"44","author":"Elmougy","year":"2021","journal-title":"J. Endocrinol. Investig."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"S341","DOI":"10.1007\/s10545-010-9181-8","article-title":"Expanded newborn screening in Greece: 30 months of experience","volume":"33","author":"Loukas","year":"2010","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_30","first-page":"e202012177","article-title":"50 years of the Neonatal Screening Program in Catalonia","volume":"94","year":"2020","journal-title":"Rev. Esp. Salud Publica"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1007\/s40618-025-02669-3","article-title":"Newborn screening for congenital adrenal hyperplasia due to 21 hydroxylase deficiency: The Italian experience 2006\u20132019","volume":"48","author":"Baronio","year":"2025","journal-title":"J. Endocrinol. Investig."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1159\/000524170","article-title":"Twenty Years of Neonatal Screening for Congenital Adrenal Hyperplasia in North-Eastern Italy: Role of Liquid Chromatography-Tandem Mass Spectrometry as a Second-Tier Test","volume":"95","author":"Cavarzere","year":"2022","journal-title":"Horm. Res. Paediatr."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1016\/j.fertnstert.2010.04.040","article-title":"Possible andrologic markers in elevated neonatal 17-hydroxyprogesterone","volume":"94","author":"Cavarzere","year":"2010","journal-title":"Fertil. Steril."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/cge.13078","article-title":"A genetic epidemiology study of congenital adrenal hyperplasia in Italy","volume":"93","author":"Gialluisi","year":"2018","journal-title":"Clin. Genet."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1093\/humupd\/dmx014","article-title":"Non-classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency revisited: An update with a special focus on adolescent and adult women","volume":"23","author":"Carmina","year":"2017","journal-title":"Hum. Reprod. Update"},{"key":"ref_36","first-page":"500","article-title":"Newborn screening for congenital adrenal hyperplasia in France","volume":"37","author":"Kariyawasam","year":"2021","journal-title":"Med. Sci."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"287","DOI":"10.4274\/jcrpe.galenos.2020.2019.0182","article-title":"Neonatal Screening for Congenital Adrenal Hyperplasia in Turkey: Outcomes of Extended Pilot Study in 241,083 Infants","volume":"12","author":"Guran","year":"2020","journal-title":"J. Clin. Res. Pediatr. Endocrinol."},{"key":"ref_38","first-page":"115","article-title":"21-Hydroxylase deficiency: Screening and incidence in Israel","volume":"48","author":"Sack","year":"1997","journal-title":"Horm. Res."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Neocleous, V., Fanis, P., Phylactou, L.A., and Skordis, N. (2018). Genotype Is Associated to the Degree of Virilization in Patients With Classic Congenital Adrenal Hyperplasia. Front. Endocrinol., 9.","DOI":"10.3389\/fendo.2018.00733"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s13023-024-03171-4","article-title":"Genetic diagnosis of endocrine disorders in Cyprus through the Cyprus Institute of Neurology and Genetics: An ENDO-ERN Reference Center","volume":"19","author":"Neocleous","year":"2024","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_41","first-page":"310","article-title":"Classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency in croatia between 1995 and 2006","volume":"72","author":"Dumic","year":"2009","journal-title":"Horm. Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1002\/ajmg.1320420617","article-title":"High frequency of congenital adrenal hyperplasia (classic 11 beta-hydroxylase deficiency) among Jews from Morocco","volume":"42","author":"Rosler","year":"1992","journal-title":"Am. J. Med. Genet."},{"key":"ref_43","first-page":"e63520","article-title":"A Cross-Sectional Study of Congenital Adrenal Hyperplasia","volume":"16","author":"Bouarab","year":"2024","journal-title":"Cureus"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Ladjouze, A., Ouarezki, Y., Djermane, A., Kherra, S., Bensalah, M., Mohammedi, K., Douiri, D., Boutaghane, N., Bouzerar, Z., and Van Vliet, G. (Horm. Res. Paediatr., 2025). Rarity of Congenital Adrenal Hyperplasia in Children Born Very Preterm: Possible Mechanism and Implication for Newborn Screening, Horm. Res. Paediatr., ahead of print.","DOI":"10.1159\/000543430"},{"key":"ref_45","first-page":"77","article-title":"Mutational analysis in Lebanese patients with congenital adrenal hyperplasia due to a deficit in 21-hydroxylase","volume":"53","author":"Delague","year":"2000","journal-title":"Horm. Res."},{"key":"ref_46","first-page":"27","article-title":"The prevalence of endocrinopathies among Lebanese women presenting with hirsutism to an endocrine clinic","volume":"62","author":"Zreik","year":"2014","journal-title":"J. Med. Liban."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1530\/EJE-20-1249","article-title":"International practice of corticosteroid replacement therapy in congenital adrenal hyperplasia: Data from the I-CAH registry","volume":"184","author":"Bacila","year":"2021","journal-title":"Eur. J. Endocrinol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1210\/js.2019-00136","article-title":"Glucocorticoid Regimens in the Treatment of Congenital Adrenal Hyperplasia: A Systematic Review and Meta-Analysis","volume":"3","author":"Whittle","year":"2019","journal-title":"J. Endocr. Soc."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s11154-022-09717-w","article-title":"Novel treatments for congenital adrenal hyperplasia","volume":"23","author":"Schroder","year":"2022","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e250565","DOI":"10.1530\/EC-25-0565","article-title":"Glucocorticoid Prescribing Trends in Congenital Adrenal Hyperplasia, 2017 to 2023","volume":"15","author":"Roxas","year":"2026","journal-title":"Endocr. Connect."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s40265-025-02165-1","article-title":"Crinecerfont: First Approval","volume":"85","author":"Lee","year":"2025","journal-title":"Drugs"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2404655","article-title":"Phase 3 Trial of Crinecerfont in Pediatric Congenital Adrenal Hyperplasia","volume":"391","author":"Sarafoglou","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1073\/pnas.0906079106","article-title":"Evolution in health and medicine Sackler colloquium: Consanguinity, human evolution, and complex diseases","volume":"107","author":"Bittles","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/ajmg.1320490104","article-title":"High frequencies of human genetic diseases: Founder effect with genetic drift or selection?","volume":"49","author":"Zlotogora","year":"1994","journal-title":"Am. J. Med. Genet."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s40618-024-02461-9","article-title":"Glucocorticoid treatment and adrenal suppression in children: Current view and open issues","volume":"48","author":"Improda","year":"2025","journal-title":"J. Endocrinol. Investig."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e240619","DOI":"10.1530\/EC-24-0619","article-title":"PERSPECTIVE: Treatment with hydrocortisone modified-release capsules in children and adolescents with congenital adrenal hyperplasia: An expert opinion","volume":"14","author":"Neumann","year":"2025","journal-title":"Endocr. Connect."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1210\/js.2019-00046","article-title":"Modified-Release Hydrocortisone: Is It Time to Change Clinical Practice?","volume":"3","author":"Stewart","year":"2019","journal-title":"J. Endocr. Soc."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1007\/s40265-025-02216-7","article-title":"The Current Treatment Landscape for Congenital Adrenal Hyperplasia","volume":"85","author":"Tonge","year":"2025","journal-title":"Drugs"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1177\/10600280251396594","article-title":"Crinecerfont: CRF1R Antagonist Approved for Treatment of Congenital Adrenal Hyperplasia","volume":"60","author":"Yuan","year":"2025","journal-title":"Ann. Pharmacother."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/5\/741\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T04:25:53Z","timestamp":1778387153000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/5\/741"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,8]]},"references-count":59,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["ph19050741"],"URL":"https:\/\/doi.org\/10.3390\/ph19050741","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,8]]}}}